Literature DB >> 17275943

Mechanisms controlling protein release from lipidic implants: effects of PEG addition.

Sandra Herrmann1, Gerhard Winter, Silke Mohl, Florence Siepmann, Juergen Siepmann.   

Abstract

Different types of tristearin-based implants for controlled rh-interferon alpha-2a (IFN-alpha) release were prepared by compression and thoroughly characterised in vitro. Hydroxypropyl-beta-cyclodextrin (HP-beta-CD) was added as a co-lyophilisation agent for protein stabilisation and different amounts of polyethylene glycol (PEG) as efficient protein release modifier. To get deeper insight into the underlying mass transport mechanisms, the release of IFN-alpha, HP-beta-CD and PEG into phosphate buffer pH 7.4 was monitored simultaneously and appropriate analytical solutions of Fick's second law of diffusion were fitted to the experimental results. Importantly, the addition of only 5-20% PEG to the lipidic implants significantly altered the resulting protein release rates and the relative importance of the underlying mass transport mechanisms. The release of IFN-alpha from PEG-free implants was purely diffusion controlled. In contrast, in PEG-containing devices other phenomena were also involved in the control of protein release: the IFN-alpha release rate remained about constant over prolonged periods of time and the total amounts of mobile IFN-alpha increased. Interestingly, the release of PEG itself as well as of HP-beta-CD from the implants remained purely diffusion controlled, irrespective of the amount of added PEG. Thus, different mass transport mechanisms govern the release of the drug, co-lyophilisation agent and release modifier out of the lipidic implants.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17275943     DOI: 10.1016/j.jconrel.2006.11.001

Source DB:  PubMed          Journal:  J Control Release        ISSN: 0168-3659            Impact factor:   9.776


  6 in total

1.  Cyclosporine A Loaded Electrospun Poly(D,L-Lactic Acid)/Poly(Ethylene Glycol) Nanofibers: Drug Carriers Utilizable in Local Immunosuppression.

Authors:  Jakub Sirc; Zuzana Hampejsova; Jana Trnovska; Petr Kozlik; Jakub Hrib; Radka Hobzova; Alena Zajicova; Vladimir Holan; Zuzana Bosakova
Journal:  Pharm Res       Date:  2017-04-12       Impact factor: 4.200

Review 2.  Accelerated in-vitro release testing methods for extended-release parenteral dosage forms.

Authors:  Jie Shen; Diane J Burgess
Journal:  J Pharm Pharmacol       Date:  2012-03-08       Impact factor: 3.765

3.  New insight into the role of polyethylene glycol acting as protein release modifier in lipidic implants.

Authors:  Sandra Herrmann; Silke Mohl; Florence Siepmann; Juergen Siepmann; Gerhard Winter
Journal:  Pharm Res       Date:  2007-03-23       Impact factor: 4.200

4.  Dissolution and oral bioavailability enhancement of praziquantel by solid dispersions.

Authors:  Yanyan Liu; Tianzi Wang; Wenya Ding; Chunliu Dong; Xiaoting Wang; Jianqing Chen; Yanhua Li
Journal:  Drug Deliv Transl Res       Date:  2018-06       Impact factor: 4.617

5.  PEG-nanolized ultrasmall selenium nanoparticles overcome drug resistance in hepatocellular carcinoma HepG2 cells through induction of mitochondria dysfunction.

Authors:  Shanyuan Zheng; Xiaoling Li; Yibo Zhang; Qiang Xie; Yum-Shing Wong; Wenjie Zheng; Tianfeng Chen
Journal:  Int J Nanomedicine       Date:  2012-07-23

6.  Nanofibers for drug delivery - incorporation and release of model molecules, influence of molecular weight and polymer structure.

Authors:  Jakub Hrib; Jakub Sirc; Radka Hobzova; Zuzana Hampejsova; Zuzana Bosakova; Marcela Munzarova; Jiri Michalek
Journal:  Beilstein J Nanotechnol       Date:  2015-09-25       Impact factor: 3.649

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.